The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.
What Market Valuation Is Forecasted For The Small Molecule Targeted Therapy Market By 2030 Starting From Its 2026 Size?
The market size for small molecule targeted therapy has experienced robust growth in recent years. This market is expected to increase from $77.29 billion in 2025 to $84.66 billion in 2026, exhibiting a compound annual growth rate (CAGR) of 9.5%. The expansion witnessed in prior periods is attributable to advancements in molecular biology research, a rising prevalence of chronic diseases, the broadening of pharmaceutical R&D pipelines, regulatory endorsement of targeted therapies, and improvements in drug screening technologies.
The small molecule targeted therapy market is projected to experience substantial expansion in the coming years, reaching a valuation of $120.64 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 9.3%. This anticipated growth during the forecast period is primarily fueled by a rising need for personalized medical strategies, the growing incorporation of genomics into pharmaceutical development, the broadening application of targeted therapies beyond cancer treatment, an increased emphasis on drug designs optimized for safety, and heightened investment in precision therapeutics. Key developments expected within this period involve the increasing advancement of target-specific drug creation, the expanding utilization of therapies that modulate pathways, a greater adoption of oral small molecule solutions, a sharpened focus on disease-specific molecular targets, and the broadening of combination small molecule treatment protocols.
Download the Free Sample Report to Explore Key Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=28332&type=smp
Which Market Drivers Are Supporting The Expansion Of The Small Molecule Targeted Therapy Market?
The increasing focus on personalized medicine is anticipated to propel the small molecule targeted therapy market forward. Personalized medicine defines a healthcare method that customizes prevention, diagnosis, and treatment based on an individual’s genetic, environmental, and lifestyle factors. The growth in personalized medicine is propelled by advancements in genomics, which facilitate a more in-depth understanding of individual genetic variations and enable more precise, targeted treatments that enhance patient outcomes and minimize trial-and-error in therapies. Small molecule targeted therapy facilitates personalized medicine by selectively addressing a patient’s specific molecular or genetic disease profile, thereby improving treatment efficacy and reducing side effects. For instance, in February 2024, data from the Personalized Medicine Coalition, a US-based non-profit organization, showed that in 2023, the FDA approved 16 new personalized treatments for rare disease patients, an increase from six in 2022. The personalized treatments newly approved in 2023 also encompassed seven cancer drugs and three for other diseases and conditions. Therefore, the growing emphasis on personalized medicine is a significant driver for the growth of the small molecule targeted therapy market.
Which Segment Categories Define The Small Molecule Targeted Therapy Market?
The small molecule targeted therapy market covered in this report is segmented –
1) By Type Of Therapy: Chemotherapy, Targeted Therapy, Immunotherapy
2) By Drug Class: Monoclonal Antibodies, Small Molecule Inhibitors, Combination Therapies
3) By Mechanism Of Action: Kinase Inhibitors, Proteasome Inhibitors, Aromatic Hydrocarbon Receptor (Ahr) Modulators, Cell Cycle Inhibitors
4) By Disease Indication: Cancer, Autoimmune Diseases, Infectious Diseases
5) By Route Of Administration: Oral, Intravenous, Subcutaneous
Subsegments:
1) By Chemotherapy: Alkylating Agents, Antimetabolites, Anti-microtubule Agents
2) By Targeted Therapy: Kinase Inhibitors, Proteasome Inhibitors, Aromatic Hydrocarbon Receptor (AhR) Modulators
3) By Immunotherapy: Immune Checkpoint Inhibitors, Cancer Vaccines, Monoclonal Antibodies
What Major Market Trends Are Driving Changes In The Small Molecule Targeted Therapy Market?
Major companies operating in the small molecule targeted therapy market are concentrating on developing innovative solutions like oral small molecules to enhance targeted delivery, improve patient compliance, and address specific molecular pathways in oncology and other chronic diseases. An oral small molecule is a low-molecular-weight drug administered orally, designed to enter cells easily and specifically target disease-related proteins or pathways. As an illustration, in June 2025, Kura Oncology Inc., a US-based biotech company, secured FDA approval for a New Drug Application (NDA) for ziftomenib. This treatment is designated for adult patients with relapsed or refractory acute myeloid leukemia (AML) with nucleophosmin 1 (NPM1) mutations. Ziftomenib, an oral targeted therapy, is tailored for adult patients with relapsed or refractory AML carrying NPM1 mutations, thereby addressing a crucial unmet medical need. It presents a favorable safety profile and has shown encouraging efficacy, including notable complete remission rates in clinical trials. By selectively inhibiting the menin-KMT2A interaction, ziftomenib disrupts leukemic cell growth and provides new treatment options for this challenging AML subtype.
Who Are The Top Companies Competing In The Small Molecule Targeted Therapy Market?
Major companies operating in the small molecule targeted therapy market are F. Hoffmann-La Roche AG (Roche), Merck KGaA, Pfizer Inc., Bayer AG, Sanofi S.A., Novartis International AG, AstraZeneca PLC, Bristol-Myers Squibb Company, GlaxoSmithKline plc (GSK), Eli Lilly and Company, Amgen Inc., Regeneron Pharmaceuticals Inc., Astellas Pharma Inc., Lonza Group AG, Blueprint Medicines Corporation, Kura Oncology Inc., G1 Therapeutics Inc., Ascentage Pharma Group International Inc., Rgenta Therapeutics Inc., Verastem Inc.
Read the full small molecule targeted therapy market report here:
How Is The Small Molecule Targeted Therapy Market Distributed Across Key Geographic Regions?
North America was the largest region in the small molecule targeted therapy market in 2025. Asia Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the small molecule targeted therapy market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request A Tailored Small Molecule Targeted Therapy Market Research Report For Competitive Advantage:
https://www.thebusinessresearchcompany.com/customise?id=28332&type=smp
Browse Through More Reports Similar to the Global Small Molecule Targeted Therapy Market 2026, By The Business Research Company
Small Molecule Drug Discovery Market Report 2026
https://www.thebusinessresearchcompany.com/report/small-molecule-drug-discovery-global-market-report
Targeted Therapy Market Report 2026
https://www.thebusinessresearchcompany.com/report/targeted-therapy-global-market-report
Rna Targeting Small Molecules Therapeutics Market Report 2026
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model